US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids: Pros and Cons, and a European Perspective

Author： Mercadante Sebastiano  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.18, 2012-12, pp. : 2327-2332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Controlled and Continuous Release Ocular Drug Delivery Systems: Pros and Cons

By  

Current Drug Delivery, Vol. 9, Iss. 4, 2012-07 ,pp. : 421-430

Bentham Science Publishers

Access to resources Recommend Favorite

Health Risk Assessment Practices in the U.S. Food and Drug Administration

By Gaylor D.W.   Axelrad J.A.   Brown R.P.   Cavagnaro J.A.   Cyr W.H.   Hulebak K.L.   Lorentzen R.J.   Miller M.A.   Mulligan L.T.   Schwetz B.A.  

Regulatory Toxicology and Pharmacology, Vol. 26, Iss. 3, 1997-12 ,pp. : 307-321

Academic Press

Access to resources Recommend Favorite

An extended-release formulation of desferrioxamine for subcutaneous administration

By Toliyat Tayebeh   Jorjani Masomeh   Khorasanirad Zeinab  

Drug Delivery, Vol. 16, Iss. 7, 2009-10 ,pp. : 416-421

Informa Healthcare

Access to resources Recommend Favorite

The pros and cons of Rx-to-OTC switching of drugs in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 474, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The pros and cons of Rx-to-OTC switching of drugs in the US

By  

Inpharma, Vol. 1, Iss. 1480-1481, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite